Aldinger K A, Schultz P N, Blumenschein G R, Samaan N A
Arch Intern Med. 1978 Nov;138(11):1638-41.
Serum thyroid-stimulating hormone (TSH) and prolactin (PRL) levels were measured before and after intravenous administration of protirelin to 148 patients with breast carcinoma. There was a high prevalence (36%) of elevated basal TSH; however, most of the patients were euthyroid and had normal serum thyroxine and T3 resin uptake. The PRL level was elevated in 22% of the cases. Both the mean PRL and the mean TSH levels for the breast cancer patients were significantly elevated above the respective means in a control group. We could find no correlation between serum TSH and PRL levels, suggesting that the purported association between a decreased thyroid state and breast cancer is probably not mediated through an increased PRL level. The mean survival and mean disease-free interval were shorter for patients with either elevated TSH or elevated PRL levels, but in neither case was the difference statistically significant.
对148例乳腺癌患者静脉注射促甲状腺素释放激素前后测定血清促甲状腺激素（TSH）和催乳素（PRL）水平。基础TSH升高的患病率较高（36%）；然而，大多数患者甲状腺功能正常，血清甲状腺素和T3树脂摄取正常。22%的病例PRL水平升高。乳腺癌患者的平均PRL和平均TSH水平均显著高于对照组的相应均值。我们未发现血清TSH与PRL水平之间存在相关性，这表明所谓的甲状腺功能减退状态与乳腺癌之间的关联可能不是通过PRL水平升高介导的。TSH升高或PRL水平升高的患者的平均生存期和平均无病间期较短，但在这两种情况下差异均无统计学意义。
